DENTSPLY SIRONA Inc (XRAY) Expected to Announce Quarterly Sales of $1.03 Billion

Wall Street analysts predict that DENTSPLY SIRONA Inc (NASDAQ:XRAY) will report $1.03 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for DENTSPLY SIRONA’s earnings, with the highest sales estimate coming in at $1.05 billion and the lowest estimate coming in at $1.02 billion. DENTSPLY SIRONA reported sales of $1.04 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 1%. The business is expected to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that DENTSPLY SIRONA will report full-year sales of $4.01 billion for the current fiscal year, with estimates ranging from $3.99 billion to $4.02 billion. For the next year, analysts forecast that the company will report sales of $4.14 billion, with estimates ranging from $4.09 billion to $4.17 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Friday, May 3rd. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. The company had revenue of $946.20 million for the quarter, compared to analyst estimates of $925.13 million. DENTSPLY SIRONA had a positive return on equity of 8.99% and a negative net margin of 26.48%. The firm’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.45 EPS.

Several research analysts have recently commented on XRAY shares. UBS Group started coverage on DENTSPLY SIRONA in a report on Thursday, January 17th. They set a “neutral” rating and a $42.00 price target on the stock. BidaskClub lowered DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 23rd. Barclays set a $49.00 price target on DENTSPLY SIRONA and gave the stock a “hold” rating in a report on Friday, March 1st. HC Wainwright reiterated a “neutral” rating and set a $49.00 price target (up previously from $40.00) on shares of DENTSPLY SIRONA in a report on Monday, March 4th. Finally, Robert W. Baird lifted their price target on DENTSPLY SIRONA from $42.00 to $50.00 and gave the stock a “neutral” rating in a report on Monday, March 4th. Eight research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $53.55.

Shares of NASDAQ XRAY traded down $0.40 during trading on Tuesday, hitting $54.49. 76,048 shares of the company were exchanged, compared to its average volume of 1,711,197. DENTSPLY SIRONA has a 12-month low of $33.93 and a 12-month high of $55.88. The company has a quick ratio of 1.35, a current ratio of 2.06 and a debt-to-equity ratio of 0.33. The firm has a market cap of $12.86 billion, a PE ratio of 27.21, a P/E/G ratio of 2.05 and a beta of 1.11.

In related news, insider William E. Newell sold 3,000 shares of the firm’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $54.73, for a total transaction of $164,190.00. Following the completion of the sale, the insider now directly owns 28,212 shares of the company’s stock, valued at approximately $1,544,042.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Coleman sold 9,160 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $54.90, for a total value of $502,884.00. Following the sale, the director now directly owns 31,383 shares of the company’s stock, valued at $1,722,926.70. The disclosure for this sale can be found here. Insiders have sold a total of 101,022 shares of company stock valued at $5,535,985 over the last three months. Corporate insiders own 0.62% of the company’s stock.

Large investors have recently modified their holdings of the stock. Advisor Partners LLC acquired a new stake in shares of DENTSPLY SIRONA during the 4th quarter worth about $367,000. S&CO Inc. increased its position in shares of DENTSPLY SIRONA by 4.3% during the 1st quarter. S&CO Inc. now owns 57,040 shares of the medical instruments supplier’s stock worth $2,829,000 after purchasing an additional 2,352 shares during the last quarter. Natixis Advisors L.P. grew its position in DENTSPLY SIRONA by 30.7% in the 4th quarter. Natixis Advisors L.P. now owns 44,911 shares of the medical instruments supplier’s stock valued at $1,671,000 after acquiring an additional 10,547 shares in the last quarter. Stone Ridge Asset Management LLC grew its position in DENTSPLY SIRONA by 50.8% in the 4th quarter. Stone Ridge Asset Management LLC now owns 29,170 shares of the medical instruments supplier’s stock valued at $1,085,000 after acquiring an additional 9,825 shares in the last quarter. Finally, AMG National Trust Bank acquired a new position in DENTSPLY SIRONA in the 4th quarter valued at about $1,379,000. 95.83% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Recommended Story: Trade Deficit

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.